GRFS — Grifols SA
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1438569 ·
Last close
$7.35
Market Cap
$1.90B
52W High
$10.09
52W Low
$6.87
ADV30
530,053
Next earnings
2026-07-28
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 1,874,000,000 | 704,000,000 | 329,000,000 | 154,000,000 | 20,090,000,000 | 513,000,000 | 12,110,000,000 |
| Mar 2026 | 1,700,000,000 | 620,000,000 | 249,000,000 | 73,000,000 | 20,078,000,000 | 702,000,000 | 12,231,000,000 |
| Dec 2025 | 1,981,660,000 | 686,841,000 | 275,377,000 | 98,250,000 | 19,712,000,000 | 801,000,000 | 12,109,000,000 |
| Jun 2025 | 1,891,131,000 | 743,795,000 | 349,541,000 | 117,063,000 | 19,767,159,000 | 558,691,000 | 12,169,006,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$924,864,000
Investing CF
$-528,321,000
Financing CF
$-623,176,000
CapEx
$-437,149,000
Dividends Paid
$-25,618,000
Buybacks
—
EPS Diluted TTM
$0.60
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$227,000,000
Inventory
$3,492,000,000
Receivables
$1,189,000,000
ST Investments
$16,000,000
EBIT TTM
$1,147,087,000
Pretax Income TTM
$661,096,000
Interest Exp TTM
$265,290,000
Analysts
2
Yahoo Snapshot (yfinance, live)
Total Revenue
$7,421,000,192
EBITDA
$1,645,230,976
Free Cash Flow
$572,923,392
Enterprise Value
$21,529,769,984
Total Cash
$537,000,000
Total Debt
$9,356,000,256
Shares Out
258,223,442
Trailing EPS
$0.77
Book Value
$4.72
ROE
6.9%
ROA
4.2%
Div Yield
3.73%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 7,524,000,000 | 1,251,000,000 | 402,000,000 | 19,712,000,000 | 12,109,000,000 | 5,271,000,000 | 1,047,000,000 |
| Dec 2024 | 7,212,000,000 | 1,155,000,000 | 157,000,000 | 21,405,000,000 | 12,799,000,000 | 5,883,000,000 | 902,000,000 |
| Dec 2023 | 6,592,000,000 | 718,000,000 | 42,000,000 | 20,992,103,000 | 13,478,408,000 | 5,368,376,000 | 217,000,000 |
| Dec 2022 | 6,063,967,000 | 678,958,000 | 185,035,000 | 21,229,584,000 | 13,253,455,000 | 5,648,523,000 | -1,427,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$1.44
Max Pain — expiry 2026-12-18
max pain strike: $7.00 · spot: $7.40 · call oi: 1,863 · put oi: 1,626
Expected Move to 2026-12-18:
±$1.15
(15.54%) —
implied range
$6.25 –
$8.55
· ATM straddle on $7.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| SDGR | Schrodinger, Inc. | $1.89B | $28.85 | — |
| ZYME | Zymeworks Inc. | $1.88B | $26.52 | — |
| GENB | Generate Biomedicines, Inc. | $1.94B | $15.15 | — |
| AGIO | AGIOS PHARMACEUTICALS, INC. | $1.95B | $32.58 | — |
| NKTR | NEKTAR THERAPEUTICS | $1.95B | $57.06 | — |
News headlines (Yahoo Finance, 1h cache)
Grifols (BME:GRF) Stock May Be Below Fair Value On Earnings
2026-09-26 15:14 · Yahoo
GRFS vs. SDZNY: Which Stock Should Value Investors Buy Now?
2026-09-24 14:40 · Yahoo
GRFS or SDZNY: Which Is the Better Value Stock Right Now?
2026-09-08 15:40 · Yahoo
European Equities Traded in the US as American Depositary Receipts Edge Higher in Tuesday Trading
2026-09-01 15:10 · Yahoo
European Equities Traded in the US as American Depositary Receipts Rise in Wednesday Trading
2026-08-19 15:18 · Yahoo
OPSEU/SEFPO: Permanently end for-profit plasma collection to protect public health
2026-08-14 18:19 · Yahoo
Grifols (GRFS) Q2 2026 Earnings Call Transcript
2026-07-29 01:12 · Yahoo
European Equities Traded in the US as American Depositary Receipts Start Week Marginally Higher in Monday Trading
2026-07-27 15:13 · Yahoo
European Equities Traded in the US as American Depositary Receipts Edge Higher in Friday Trading; Down for Week
2026-09-25 15:15 · Yahoo
European Equities Traded in the US as American Depositary Receipts Drop in Thursday Trading
2026-09-10 15:34 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.